Jasper Therapeutics Completes IgA Nephropathy Enrollment in Phase 2 Vensobafusp Alfa Trial
Jasper Therapeutics completed IgA nephropathy enrollment in its Phase 2 renal basket trial of vensobafusp alfa (KP104), enrolling 18 patients. Initial interim results are expected by year-end 2026 to assess safety, tolerability and early efficacy. An accelerated expansion into focal segmental glomerulosclerosis targets